Advertisement

Topics

Nuformix Plc kicks off clinical trial for its chemo side effect drug

04:51 EDT 26 Mar 2019 | Proactive Investors

Dan Gooding, chief executive of Nuformix Plc (LON:NFX), speaks to Proactive London's Andrew Scott soon after announcing they'd begun clinical studies for their lead asset NXP001.

Gooding explains NXP001 is in development as a treatment for chemotherapy-induced nausea and vomiting, which he says is an under-exploited and growing market affecting close to a third of global cancer patients.

Original Article: Nuformix Plc kicks off clinical trial for its chemo side effect drug

NEXT ARTICLE

More From BioPortfolio on "Nuformix Plc kicks off clinical trial for its chemo side effect drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...